



FROM THE REPAIR PROCESS TO TISSUE RIGENERATION

**THE NEW CARE METHODOLOGY
.... FROM THE PAST TO THE FUTURE**



**REGENERATIVE MEDICINE OF CMR-HMD: THE
TREATMENT OF CHRONIC WOUNDS NOT
RESPONDER**



**ARE THERE
HARD
WOUNDS ?**



**OR DO NOT
WE KNOW
HOW TREAT
THEM ?**

AIMED PROTOCOL REDUCED THE HEALING TIMES AND COSTS OF THERAPY



ARE THERE HARD WOUNDS ?



- 1.INTRODUCTION
- 2.PARTNERSHIP BETWEEN
ALFAKJN AND CMR
- 3.WHY REGENERATION 3.0?
- 4.EVALUATION ON CORAKJN
PRODUCTS
- 5.PROTOCOL
- 6.CASE STUDIES
- 7.CONCLUSION

PROTOCOL REDUCED THE HEALING TIMES AND COSTS OF THERAPY



1



INTRODUCTION

THE PRODUCTS OR DEVICES OF THE ALFAKJN LINE HAVE BEEN REGISTERED IN CLASS IIB AND THEREFORE INTENDED FOR THE TREATMENT OF WOUNDS AND SUPERFICIAL AND DEEP LESIONS THANKS TO A CAREFUL ANALYSIS OF THE COMPONENTS AND THE CLAIMS OF THE SAME.

THE NEED TO ATTRIBUTE A SCIENTIFIC VALUE TO THE PHILOSOPHY OF USING THE DEVICES FRAMED IN A MULTIDISCIPLINARY WORKING METHOD AIMED AT GIVING ADDED VALUE TO THE ACTION OF THE MEDICAL DEVICE IN THE REGENERATIVE FIELD.





PARTNERSHIP BETWEEN ALFAKJN AND CMR

THE ALFAKJN WOUND CARE PROJECT IS EMBRACED BY CRM BECAUSE **INNOVATIVE** AND BECAUSE IT ANTICIPATES THE NEXT GOALS OF **REGENERATIVE MEDICINE**: SPECIFIC AND INDIVIDUAL CELL THERAPIES.

GROWTH FACTORS ENTER THE CLINICAL PRACTICE IN A DISRUPTIVE WAY AND THE CHOICE TO FOCUS ON THE QUALITY AND COMPETENCE OF PRODUCTS THAT CONTAIN THEM IS STRATEGIC FOR THE NEAR FUTURE.

DEVICES CAN BE USED ALONE OR IN SYNERGY WITH SECONDARY MEDICATIONS





Why Regeneration 3.0?

REPAIR

1.0

Use of Advanced Dressings to protect injuries





- REPAIR
- 1.0
- Use of Advanced Dressings to protect injuries
- The functions that are required today for Advanced Dressings are:
 - Maintenance of adequate moisture in the wound
 - Occlusion or semiocclusiveness,
 - Absorption of the exudate
 - The advanced medications on the market are mostly passive, in the sense that their function is determined by the metabolism and the biological performances of the patient with injury.





REPAIR

2.0

Use of Bioactive Dressings with biological action on lesions



REPAIR

2.0

USE OF BIOACTIVE DRESSINGS WITH BIOLOGICAL ACTION ON LESIONS

IN THE CASE OF CORAKJN GARZE THE PRESENCE OF BIOLOGICAL SUBSTANCES, WHOSE ROLE IS EXPLICITLY DEFINED IN LITERATURE (HANA AND CARNOSINA), DETERMINE AN IDENTIFICATION AS ADVANCED BIOACTIVE MEDICATION, WITH DEFINED AND REGULATED INDICATIONS OF USE.

CORAKJN STERILE GAUZE IS A VALID AND APPLICABLE MEDICATION TO OBTAIN A RAPID RESPONSE IN THE WOUND HEALING PROCESS AND FOR A VALID PROCESS OF TISSUE REPAIR AND REGENERATION



3.0 our innovative approach



1



A complete product line for Regeneration 3.0

Medical device class IIB

Treatment of cutaneous conditions, stage I and II pressure sores, vascular lesions in the re-epithelialization phase, and simple and complex dermatological lesions.

PARAF Code W2F81Y

Medical device class IIB

Treatment of epidermal and papillary dermal lesions and first and second degree burns, including radiodermatitis.

PARAF Code W2F82B

Medical device class IIB

Treatment of irreversible pressure-induced erythema or epidermal and dermal lesions (vascular lesions, pressure sores affecting the papillary dermis).

PARAF Code W2F834

Medical device class IIA

Treatment of all types of mucositis, stomatitis and oral mutilations, including those induced by chemo- or radiotherapy.

PARAF Code W2F89W

Medical device class IIB

10 ready-to-use non-adherent sterile gauze dressings, 10 x 10 cm, individually wrapped. The dressings consist of medicated hydrophilic gauze containing high molecular weight hyaluronic acid and camosine.

PARAF Code W2F83W

HUMANITAS
MATER DOMINI



AMR
Ambulatorio di
Medicina Rigenerativa





**OFFER AN INNOVATIVE SOLUTION
FOR A ALREADY EXISTING PROBLEM**

AIMED PROTOCOL REDUCED THE HEALING TIMES AND COSTS OF THERAPY



1. EVALUATION ON CORAKJN PRODUCTS

CORAKJN C (GEL AND SPRAY) IS INDICATED AND INTENDED FOR THE OUTPATIENT AND DOMICILIARY APPLICATION ON ACUTE AND CHRONIC LESIONS OF THE SKIN FROM VARIOUS ETIOPATHOGENESIS.

CORAKJN CREAM IS INTENDED FOR THE TREATMENT OF THE MOST SERIOUS AND COMPLEX SKIN AND MUCOUS LESIONS.

THE DEVICES WILL BE CALLED GEL DEVICE AND B CREAM DEVICE

IN THEIR COMPOSITION THE DIFFERENCE LIES IN THE QUANTITY OF ONE OF THE ACTIVE INGREDIENTS THAT DIFFERENTIATES THE ALFAKJN LINE FROM THE OTHERS AND THAT HAS AFFECTED THE CRM, NAMELY THE BOVINE COLOSTRUM PRESENT IN THE DEVICE. IN THE B DEVICE THE COLOSTRUM IS PRESENT MORE WITH A GREATER ACTION AND EFFICACY IN THE MOMENTS OF THE LESION EVOLUTION AS WELL AS BEING ASSOCIATED WITH ANOTHER COMPONENT THAT IS SIGNIFICANTLY IMPORTANT FOR THE REGENERATION PROCESS (HYALURONIC ACID).

PLEASE REFER TO THE TECHNICAL DATA SHEET OF THE TWO DEVICES THE UNDERLINING OF COMPOSITIONS AND COMPOSITION DIFFERENCES.






Figura 1. Protocollo operativo AIMED per il trattamento delle ferite croniche.

THE MEDICATION **PROTOCOL** DEVELOPED BY CRM IS CALLED **AIMED (ANTI INFLAMMATORY AND REGENERATIVE MEDICINE)** AND CONTAINS IN THE CIRCULAR PHASES OF APPROACH TO DERMATOLOGICAL INJURY THE PRINCIPLES OF A SYSTEMIC APPROACH TO THE PATIENT AND OBVIOUSLY LOCAL WITH THE NEW INTERACTIVE AND BIOLOGICAL MEDICATIONS.





PROTOCOLS OF USE

**LESIONS OF ELEMENTARY SKINS,
INJURY OF DEBUTS OF I AND II GRADO,
VASCULAR LESIONS IN REGENERATIVE
PHASE**

**INJURY OF BURNS OF I AND II GRADO
SIMPLE AND COMPLEX DERMATOPATHY
LESIONS (COSMETIC DERMATOLOGICAL
AREA)**





The application protocol elaborated by the CRM provides:

a)cleansing phase of the lesion and the surrounding skin with specific and regularly marketed products (amukimed and prontosan) that are used to compress (10 min)

b)phase of debridement of the simple lesion with removal of non-viable tissues

c)regenerative phase with application of the device A both in the form of a gel or a spray form (chosen in the extended pathologies, in particularly painful lesions)

d)waiting phase of the absorption of the DA

phase of the secondary dressing that in cases of simple injury associates the DA with the medicated gauze (abraxin or non-AD gauze)

e)cover with gauze and ev bandage

The dressing scheme must be repeated every other day

In Burns by virtue of the exudate and by virtue of the regenerative power of the DA we recommend daily dressings with the spray.



LESIONS OF COMPLEX SKUTE

III AND IV STADIUM INJURY LESIONS

STAGE BURNS OF III STAGE

COMPLETE AND INFECT VASCULAR LESIONS

VASCULITIC LESIONS



The application protocol of Device B provides for the application of the cream in good quantities for the intrinsic capacity of the product to intervene in the hydration phase of the lesion and in the subsequent phases of repair and stimulation of the regenerative phases.



The protocol provides


cleansing phase (as above)
application phase of the bedsores.
secondary dressing phase (alginates or hydrophilic depending on the exudate)
coverage and bandage phase



The dressing scheme should be repeated from 2 to 3 days.
The debridement action should be followed by the initial phase of application of bedsores for the beneficial and wetting action that has hyaluronic acid and colostrum.
The regenerative drive is assured by the quantity of product existing in the bedsores.

CORAKJN C (Gel and Spray)

Clinical experience





Ustione di II

Applicazione del DM gel in PS
Medicazione ogni 2 gg con DM
gel

Dopo 10 gg medicazione con
DM Spray

Durata 3 settimane





THE TO AIMED PROTOCOL REDUCED THE HEALING TIMES AND COSTS OF THERAPY

Ustione di II

Applicazione del DM gel in PS
Medicazione ogni 2 gg con DM gel

Dopo 10 gg medicazione con
DM Spray

Durata 2 settimane



Ustione di II grado trattata con DM Spray



Ustione di II grado trattata con DM gel in trattamento



HUMANITAS
MEDICAL CARE

Ustione di II grado trattata con DM gel in 4 settimane





THE AIMED PROTOCOL REDUCED THE HEALING TIMES AND COSTS OF THERAPY


Ustione di II grado trattata con DM spray in una



CORAKJN

integrated therapy


Clinical experience







ipergranulazione

lesione cronica su
malformazione vascolare



E HEALING TIMES AND COSTS OF THERAPY




THE AIMED PROTOCOL REDUCED THE HEALING TIMES AND COSTS OF THERAPY



RIGENERAZIONE 3.0 Terapia flessibile e completa


Associabile con tutte le medicazioni secondarie e bendaggi.



THE AIMED PROTOCOL REDUCED THE HEALING TIMES AND COSTS OF THERAPY



THE TO AIMED PROTOCOL REDUCED THE HEALING TIMES AND COSTS OF THERAPY




THE TO AIMED PROTOCOL REDUCED THE HEALING TIMES AND COSTS OF THERAPY



THE AIMED PROTOCOL REDUCED THE HEALING TIMES AND COSTS OF THERAPY







THE NEXT STEP WAS THE APPLICATION OF THE GEL AND EXPOSURE OF THE LESION TO THE LIGHT SOURCE MULTILED FOR 5 MINUTES AND IN SOME CASES TO 8 MIN.





AFTER THE GEL REMOVAL THE LESION WAS TREATED WITH THE AIMED METHOD, AND IN PARTICULAR WITH THE SECOND TOPICALLY PHASE (APPLICATION OF A DM FOR THE ACCELERATION OF THE REGENERATIVE PROCESS) AND WITH THE SECOND SYSTEMIC PHASE (USE OF ANTI-INFLAMMATORY THERAPY WITH DIETARY SUPPLEMENTATION AND WITH EV THERAPY LOW DOSE) ALL PATIENTS WERE TREATED WITH A VASCULAR BANDAGE IN THE LIMB AFFECTED BY CHRONIC LESION.







RIGENERAZIONE 3.0

Terapia flessibile e completa

Associabile con tutte le medicazioni secondarie e bendaggi.





FROM THE REGENERATIVE POINT , THE INTERESTING FACT IS THE THRUST TO THE MODULATION OF INFLAMMATORY AND PROLIFERATIVE PROCESS OF A BIOPHYSICAL THERAPY, INTEGRATED INTO A WELL-DEFINED THERAPEUTIC PROTOCOL, WHICH ON THE BASIS OF THE TYPE OF THE LESION AND THE PATIENT CAN DIVERSIFY, ACCORDING TO THE AIMED OPERATING PROTOCOL, AND IN PERFECT HARMONY WITH THE GUIDELINES THAT GIVE INDICATIONS ON ADVANCED USING MEDICATIONS.




THE LUMIHEAL THERAPY ASSOCIATED TO AIMED PROTOCOL REDUCED THE HEALING TIMES AND COSTS OF THERAPY







**THE TREATMENT WAS APPLIED
AFTER CHECKING AND INTEGRATED
AS THE METHOD AIMED AND IN
PARTICULAR THE FIRST PHASE OF
TREATMENT HAS BEEN THE
CLEANSING PHASE. IN CASES OF
PSEUDOMONAS AERUG THE LESION
WAS TREATED IN ADDITION TO THE
REGULAR PRODUCTS ON THE
MARKET WITH ACETIC ACID PACK
5%. DURING THIS PHASE, THE
LESION IS EXPOSED TO LUMIHEAL
PROTOCOL.**





THE LUMIHEAL THERAPY ASSOCIATED TO AIMED PROTOCOL REDUCED THE HEALING TIMES AND COSTS OF THERAPY



THE CORAKJN THERAPY AND AIMED PROTOCOL REDUCED THE HEALING TIMES AND COSTS OF THERAPY



THE CORAKJN THERAPY AND AIMED PROTOCOL REDUCED THE HEALING TIMES AND COSTS OF THERAPY











Conclusions

THE MOST RELEVANT ASPECT FOR THE PROSPECT OF NEW THERAPIES IN THE FIELD OF TISSUE REGENERATION AND THEREFORE AS A FUNCTION OF THE CONTROL OF THE INFLAMMATORY PROCESS CONCERNS THE DATA ON THE DISAPPEARANCE OF THE LESIONS AND THE REDUCTION OF THE INFLAMMATORY PROCESS. THIS IMPLIES A FUTURE CONSIDERATION ON THE TIME OF ACTION OF THE MDS AND ON THE CONTACT TIME OF THE MDS WITH THE AFFECTED TISSUE.

THE DATA ON THE HEALING OF THE CLINICAL PICTURE TAKES INTO ACCOUNT CHRONIC PATHOLOGIES CALLED NON-RESPONDERS AND BEING WELL MANAGED FROM THE FIRST MOMENT AFTER THE CLASSIFICATION

THE DATA ON PATIENT COMPLIANCE WITH THE USE OF THE DEVICE IS INTERESTING AND HIGHLIGHTS AN ABSENCE OF SYMPTOMS OR SIDE EFFECTS THAT SECURES THE PATIENT AND ABOVE ALL INCREASES THE RELIABILITY OF THE MDS, INCREASING ITS EFFECTIVENESS.